Across TCGA pan-cancer cohorts, MIR892A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR892A data layer compared with 5 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher MIR892A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR892A expression acts as an unfavorable survival marker.
ESCA are the cancer types where MIR892A Mutation most reproducibly stratifies survival.